Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – September 15, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to …
Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – September 3, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to …
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce that its wholly owned subsidiary, Innocan Pharma Ltd. (“Innocan Israel“) …
Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – August 6, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to …
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce that it has received notice from the FDA that Innocan’s …
InnoCan Pharma Corporation (CNSX: INNO) (FSE: IP4), is pleased to announce its collaboration with Recipharm, Israel to synthesize and analyze cannabinoid loaded exosomes. Recipharm unites …
Innocan Pharma Corporation (CNSX: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce that Mackie Research Capital Corporation’s institutional sales group has issued …
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) is pleased to announce the closing of its marketed short form prospectus offering pursuant to which the Company …
Pursuant to the amended terms, the Offering of Units will be conducted at a price of $0.18 per Unit for minimum gross proceeds of $2,500,000 …
